- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07951684
Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)
Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study
The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Aurora Mirabile Medical oncologist
- 전화번호: +39 02 2643 3526
- 이메일: mirabile.aurora@hsr.it
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants are willing and able to give informed consent for participation in the study.
- Aged >=18 years
- Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
- Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
- Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
Exclusion Criteria:
- Patients with a history of allergy to probiotics or severe allergic constitution
- Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
- Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
- Any previous RT to the head and neck region
- Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
- Allergies: history of known allergies to probiotics or to product excipients.
- Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
- Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
- Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
- Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
- Pregnancy and breastfeeding
- Contraindication related to probiotic composition
- Primary sites different from the ones described in inclusion criteria
- Patient unfit to cisplatin
- Immunocompromised Patients
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: placebo group
The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration |
|
실험적: group treated with probiotic: Streptococcus salivarius Evol12®
The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient. Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. |
Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EORTC QLQ-H&N35 score
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
days
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Time to onset (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Duration (days) of WHO grade ≥2 and ≥3. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Numeric Rating Scale (NRS)
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
Percentage
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%). |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
|
days
기간: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity. |
It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .